Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 3—March 2017

Research Letter

Successful Treatment of Human Plague with Oral Ciprofloxacin

Titus Apangu, Kevin Griffith1, Janet Abaru, Gordian Candini, Harriet Apio, Felix Okoth, Robert Okello, John Kaggwa, Sarah Acayo, Geoffrey Ezama, Brook Yockey, Christopher Sexton, Martin Schriefer, Edward Katongole Mbidde, and Paul S. MeadComments to Author 
Author affiliations: Uganda Virus Research Institute, Entebbe, Uganda (T. Apangu, J. Abaru, G. Candini, H. Apio, F. Okoth, R. Okello, J. Kaggwa, S. Acayo, G. Ezama, E.K. Mbidde); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (K. Griffith, B. Yockey, C. Sexton, M. Schriefer, P. Mead)

Cite This Article

Close

Highlight and copy the desired format.

EID Apangu T, Griffith K, Abaru J, Candini G, Apio H, Okoth F, et al. Successful Treatment of Human Plague with Oral Ciprofloxacin. Emerg Infect Dis. 2017;23(3):553-555. https://dx.doi.org/10.3201/eid2303.161212
AMA Apangu T, Griffith K, Abaru J, et al. Successful Treatment of Human Plague with Oral Ciprofloxacin. Emerging Infectious Diseases. 2017;23(3):553-555. doi:10.3201/eid2303.161212.
APA Apangu, T., Griffith, K., Abaru, J., Candini, G., Apio, H., Okoth, F....Mead, P. S. (2017). Successful Treatment of Human Plague with Oral Ciprofloxacin. Emerging Infectious Diseases, 23(3), 553-555. https://dx.doi.org/10.3201/eid2303.161212.

Abstract

The US Food and Drug Administration recently approved ciprofloxacin for treatment of plague (Yersina pestis infection) based on animal studies. Published evidence of efficacy in humans is sparse. We report 5 cases of culture-confirmed human plague treated successfully with oral ciprofloxacin, including 1 case of pneumonic plague.

Plague is a life-threatening zoonotic disease caused by Yersinia pestis. Zoonotic foci exist on several continents; however, resource-poor areas in sub-Saharan Africa account for most human cases (1). The pathogenesis of plague involves facultative intracellular infection of host macrophages, followed by fulminant extracellular growth and bacteremia (2). In the absence of effective antimicrobial drug treatment, bubonic plague is fatal in ≈50% of cases and pneumonic plague in >90% (1,3).

Drugs approved by the US Food and Drug Administration (FDA) for treatment of plague include streptomycin and doxycycline. Streptomycin is bactericidal but rarely used because of limited availability and serious toxicities. Doxycycline is bacteriostatic and lacks concentration-dependent activity or a postantibiotic effect, which might limit its efficacy for serious Y. pestis infections (4). Nevertheless, low cost and oral dosing have made doxycycline a first-line treatment in several countries (5,6). Fluoroquinolones, include ciprofloxacin, have recently been approved by the FDA for treatment of plague based on animal and in vitro studies (4,7,8). Clinical experience with these agents, however, is limited (1,5).

During 2011–2014, patients with suspected plague seen at 6 clinics and 2 hospitals in the West Nile region of Uganda were offered enrollment in an open-label study evaluating the safety and efficacy of ciprofloxacin for treatment of plague. Patients were excluded if they were pregnant, <8 years of age, considered too ill to receive oral treatment, or had received antimicrobial drug treatment in the preceding 7 days. After written consent was obtained, diagnostic samples were collected and oral ciprofloxacin administered for 10 days at a weight-calibrated dosage of ≈15 mg/kg twice daily (range 13–17 mg/kg), with a maximum dose for adults of 750 mg twice daily. Diagnostic samples were cultured on sheep blood agar and suspect isolates confirmed by bacteriophage lysis (9). Patients were monitored daily during treatment, and clinical outcome was assessed 14–21 days after initial evaluation. Because of simultaneous prevention efforts and lower than expected enrollment, the study was terminated early. The study was approved by Institutional Review Boards at the Uganda Virus Research Institute, the Uganda National Council for Science and Technology, and the US Centers for Disease Control and Prevention.

Five patients with culture-confirmed plague were enrolled and treated with oral ciprofloxacin (Table). Median patient age was 27 years (range 10–52 years); median time between illness onset and enrollment was 4 days (range 1–7 days). Four patients had bubonic plague, with Y. pestis isolated from bubo aspirates or blood cultures. The fifth patient, a 13-year-old boy, had pneumonic plague as indicated by hemoptysis, patchy bilateral infiltrates on chest radiograph, and Y. pestis isolated from sputum. The illness had evolved over 6 days, a clinical course suggestive of secondary rather than primary pneumonic plague (3); the primary focus of infection was not identified.

Three patients were admitted and 2 treated as outpatients. In addition to ciprofloxacin, all received acetaminophen, and 2 received a bolus of normal saline. All became afebrile within 2 days. At 14 days, all had been discharged and returned to their normal activities. The 13-year-old boy with culture-confirmed pneumonic plague reported mild, nonproductive cough, but no complications were identified.

Fluoroquinolones have pharmacokinetic properties that make them attractive for treatment of plague, including bactericidal activity, good oral bioavailability, excellent tissue penetration, and an established safety record (8,10). In vitro assays suggest that ciprofloxacin is comparable to streptomycin and superior to doxycycline or gentamicin for killing of intracellular Y. pestis (4), and efficacy has been demonstrated in rodent and nonhuman primate models (8). Along with FDA approval, our results add to growing clinical experience (5) and support the broader use of oral ciprofloxacin for treatment of human plague, especially in resource-poor areas where intravenous treatment is limited.

Dr. Apangu is a clinical officer and leads the Epidemiology Team at the Uganda Virus Research Institute’s Plague Field Station in Aura. His research interests include epidemiology, vectorborne diseases, and public health.

Acknowledgments

The authors are grateful for the assistance of all staff of the participating clinics, members of the Data Safety Monitoring Board, Jeff Borchert, and Kiersten Kugeler.

The work was supported by the Centers for Disease Control and Prevention (Cooperative Agreement CK13001).

References

  1. Butler T. Plague gives surprises in the first decade of the 21st century in the United States and worldwide. Am J Trop Med Hyg. 2013;89:78893. DOIPubMed
  2. Zhou D, Han Y, Yang R. Molecular and physiological insights into plague transmission, virulence and etiology. Microbes Infect. 2006;8:27384. DOIPubMed
  3. Pollitzer R. Plague. Geneva: World Health Organization; 1954.
  4. Wendte JM, Ponnusamy D, Reiber D, Blair JL, Clinkenbeard KD. In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis. Antimicrob Agents Chemother. 2011;55:37527. DOIPubMed
  5. Raoult D, Mouffok N, Bitam I, Piarroux R, Drancourt M. Plague: history and contemporary analysis. J Infect. 2013;66:1826. DOIPubMed
  6. Mwengee W, Butler T, Mgema S, Mhina G, Almasi Y, Bradley C, et al. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin Infect Dis. 2006;42:61421. DOIPubMed
  7. US Food and Drug Administration. sNDA approval–animal efficacy: ciprofloxacin [cited 2016 Jun 13]. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/019537Orig1s083,019847Orig1s055,019857Orig1s063,020780Orig1s041ltr.pdf
  8. National Institute of Allergy and Infectious Diseases. Treatment of pneumonic plague: medical utility of ciprofloxacin [cited 2016 Jun 13]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM297865.pdf
  9. Chu MC. Laboratory manual of plague diagnostic tests. Washington: US Department of Health and Human Services; 2000.
  10. Hooper D, Strahilevitz J. Quinolones. In: Bennett J, Dolin R, Blaser M, editors. Principles and practice of infectious diseases. 8th ed. Vol. 1. New York: Elsevier; 2015. p. 419–39.

Table

Cite This Article

DOI: 10.3201/eid2303.161212

1Current affiliation: Fort Lewis College, Durango, Colorado, USA.

Table of Contents – Volume 23, Number 3—March 2017

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Author for correspondence: Paul Mead, Centers for Disease Control and Prevention, 3156 Rampart Rd, Fort Collins, CO 80521, USA


character(s) remaining.

Comment submitted successfully, thank you for your feedback.

TOP